AR124078A1 - Método para el tratamiento de la enfermedad de parkinson - Google Patents
Método para el tratamiento de la enfermedad de parkinsonInfo
- Publication number
- AR124078A1 AR124078A1 ARP210103172A ARP210103172A AR124078A1 AR 124078 A1 AR124078 A1 AR 124078A1 AR P210103172 A ARP210103172 A AR P210103172A AR P210103172 A ARP210103172 A AR P210103172A AR 124078 A1 AR124078 A1 AR 124078A1
- Authority
- AR
- Argentina
- Prior art keywords
- ddci
- levodopa
- combination
- salt
- prodrug
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 abstract 19
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 abstract 19
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 14
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 10
- 229960004502 levodopa Drugs 0.000 abstract 10
- 239000008194 pharmaceutical composition Substances 0.000 abstract 8
- 239000000651 prodrug Substances 0.000 abstract 8
- 229940002612 prodrug Drugs 0.000 abstract 8
- 150000003839 salts Chemical class 0.000 abstract 4
- 208000016285 Movement disease Diseases 0.000 abstract 3
- 208000012902 Nervous system disease Diseases 0.000 abstract 3
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 abstract 2
- 229960000911 benserazide Drugs 0.000 abstract 2
- 229960004205 carbidopa Drugs 0.000 abstract 2
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000000926 neurological effect Effects 0.000 abstract 2
- 238000007911 parenteral administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se divulga un método para el tratamiento de un trastorno neurológico o del movimiento, p. ej., la enfermedad de Parkinson, en un individuo que lo necesita, mediante la administración parenteral de levodopa y un inhibidor de la descarboxilasa dopa (DDCI), tal como carbidopa, benserazida o cualquier combinación de estos, de manera concomitante con la administración oral de levodopa, un DDCI, tal como carbidopa, benserazida, o cualquier combinación de estos. Reivindicación 30: Una primera composición farmacéutica caracterizada porque comprende: levodopa, una sal de levodopa, un profármaco de levodopa, o cualquier combinación de estos; y un inhibidor de la dopa descarboxilasa (DDCI), una sal de DDCI, un profármaco de DDCI, o cualquier combinación de estos; y, una segunda composición farmacéutica que comprende: levodopa, una sal de levodopa, un profármaco de levodopa, un inhibidor de la dopa descarboxilasa (DDCI), una sal de DDCI, un profármaco de DDCI; o cualquier combinación de estos, para su uso como combinación en el tratamiento de un trastorno neurológico o del movimiento, donde la primera composición farmacéutica se formula como una composición parenteral y la segunda composición farmacéutica se formula como una composición oral. Reivindicación 31: Un equipo caracterizado porque comprende: una primera composición farmacéutica en forma parenteral que comprende: levodopa, una sal de levodopa, un profármaco de levodopa, o cualquier combinación de estos; y un inhibidor de la dopa descarboxilasa (DDCI), una sal de DDCI, un profármaco de DDCI, o cualquier combinación de estos; una segunda composición farmacéutica en forma oral que comprende: levodopa, una sal de levodopa, un profármaco de levodopa, un inhibidor de la dopa descarboxilasa (DDCI), una sal de DDCI, un profármaco de DDCI; o cualquier combinación de estos; y instrucciones para la administración concomitante de la primera composición farmacéutica y la segunda composición farmacéutica para el tratamiento de un trastorno neurológico o del movimiento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063114688P | 2020-11-17 | 2020-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124078A1 true AR124078A1 (es) | 2023-02-08 |
Family
ID=79169649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103172A AR124078A1 (es) | 2020-11-17 | 2021-11-17 | Método para el tratamiento de la enfermedad de parkinson |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11213502B1 (es) |
| EP (1) | EP4247357A4 (es) |
| JP (1) | JP2023552700A (es) |
| KR (1) | KR20230110542A (es) |
| CN (1) | CN117120045A (es) |
| AR (1) | AR124078A1 (es) |
| AU (1) | AU2021383322A1 (es) |
| CA (1) | CA3198748A1 (es) |
| IL (1) | IL302826A (es) |
| MX (1) | MX2023005725A (es) |
| TW (1) | TW202233171A (es) |
| WO (1) | WO2022107125A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12251365B2 (en) | 2018-11-15 | 2025-03-18 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| WO2023126945A1 (en) * | 2022-01-03 | 2023-07-06 | Neuroderm, Ltd. | Methods and compositions for treating parkinson's disease |
| CN120936350A (zh) * | 2023-04-14 | 2025-11-11 | 纽罗德姆有限公司 | 用于减轻帕金森病的症状的方法和组合物 |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
| WO2025176317A1 (en) | 2024-02-23 | 2025-08-28 | Laxxon Medical Ag | Multicompartment compositions in the treatment of parkinson's disease |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3808317A (en) | 1969-10-29 | 1974-04-30 | Alcon Labor Inc | Stabilized aqueous borate complexes of biologically active catechol amines |
| US3769424A (en) | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
| AU6889274A (en) | 1973-05-17 | 1975-11-20 | Astra Laekemedel Ab | Treatment of neurological disorders |
| US3936495A (en) | 1973-11-27 | 1976-02-03 | Merck & Co., Inc. | Purification process |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4241082A (en) | 1977-09-02 | 1980-12-23 | Sankyo Company Limited | Agents for promoting reproductive ability of domestic animals |
| JPS5450700A (en) | 1977-09-28 | 1979-04-20 | Sankyo Co | Glazing agent of animal leather |
| JPS6021570B2 (ja) | 1978-07-04 | 1985-05-28 | 三共株式会社 | ド−パ類の高濃度製剤の製法 |
| JPS56115749A (en) | 1980-02-18 | 1981-09-11 | Sagami Chem Res Center | Dopa derivative |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4642316A (en) | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| DE252290T1 (de) | 1986-06-10 | 1988-06-09 | Chiesi Farmaceutici S.P.A., Parma | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| US4832957A (en) | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4684666A (en) | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
| IT1226902B (it) | 1988-07-12 | 1991-02-21 | Mini Ricerca Scient Tecnolog | Processo per la sintesi del levodopa |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| CA2058975C (en) | 1990-10-30 | 2000-06-06 | Shuichi Kasai | Antiinflammatory gel preparation |
| US5877176A (en) | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| CA2143070C (en) | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
| FI974323A7 (fi) | 1995-05-26 | 1997-11-25 | Pfizer | Selektiivisiä NMDA-antagonisteja sisältäviä yhdistelmiä parkinsonismin hoitoa varten |
| GB9523833D0 (en) | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| IL119417A (en) | 1996-10-13 | 2003-02-12 | Moshe Kushnir | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
| US6746688B1 (en) | 1996-10-13 | 2004-06-08 | Neuroderm Ltd. | Apparatus for the transdermal treatment of Parkinson's disease |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| WO1999048876A1 (en) | 1998-03-20 | 1999-09-30 | Warner-Lambert Company | Crystalline sodium phenytoin monohydrate |
| US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| CN1303991C (zh) | 1998-05-15 | 2007-03-14 | 沃尼尔·朗伯公司 | γ－氨基丁酸衍生物的稳定药物制剂和其制备方法 |
| US6274168B1 (en) | 1999-02-23 | 2001-08-14 | Mylan Pharmaceuticals Inc. | Phenytoin sodium pharmaceutical compositions |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| WO2000054773A1 (en) | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US7479498B2 (en) | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
| US6348965B1 (en) | 1999-09-24 | 2002-02-19 | Henry Palladino | Solid state fluorescence and absorption spectroscopy |
| SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
| US20020028799A1 (en) | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| GB0017387D0 (en) | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
| US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| US20030119714A1 (en) | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| MXPA03005609A (es) | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
| IL159812A0 (en) | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core |
| ES2561108T3 (es) | 2001-10-19 | 2016-02-24 | Idexx Laboratories, Inc. | Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo |
| EP1450901A4 (en) | 2001-12-10 | 2005-05-25 | Bristol Myers Squibb Co | (1-PHENYL-2-HETEROARYL) ETHYL-GUANIDINE COMPOUNDS AS AN INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE |
| ES2189682B1 (es) | 2001-12-11 | 2004-04-01 | Laboratorios Del Dr. Esteve, S.A. | Preparacion bebible que comprende ketoprofeno y su empleo en el tratamiento de procesos que cursan con fiebre, inflamacion y/o dolor, en un colectivo de animales, de forma simultanea. |
| WO2003084514A1 (en) | 2002-04-11 | 2003-10-16 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical compositions of carbidopa and levodopa |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| BR0315221A (pt) | 2002-10-10 | 2005-08-23 | Morphochem Ag Komb Chemie | Compostos com atividade antibacteriana |
| WO2004069146A2 (en) | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-dopa amide derivatives and uses thereof |
| AU2004280158B2 (en) | 2003-07-18 | 2011-02-17 | Baxter International, Inc. | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
| US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
| US20050070608A1 (en) | 2003-08-29 | 2005-03-31 | Julius Remenar | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US20050053669A1 (en) | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
| CA2543945A1 (en) | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (sv) | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| EP1797109B1 (en) | 2004-09-09 | 2016-02-24 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| US20060241183A1 (en) | 2004-09-28 | 2006-10-26 | Farouk Karoum | Compositions and methods of using D-DOPA to treat Parkinson's disease |
| AU2005292184A1 (en) | 2004-10-01 | 2006-04-13 | The Research Foundation Of State University Of New York | Morphine and morphine precursors |
| WO2006043532A1 (ja) | 2004-10-19 | 2006-04-27 | Ono Pharmaceutical Co., Ltd. | パーキンソン病治療剤 |
| ES2311442T3 (es) | 2005-06-08 | 2010-01-07 | Orion Corporation | Un metood para la fabricacion de granulos que contienen entacapona para formas de dosificacion oral. |
| DE102006021872B4 (de) | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| BRPI0711882A2 (pt) | 2006-05-31 | 2012-01-10 | Solvay Pharm Gmbh | administração intestinal de longo termo durante 24 horas de levodopa/carbidopa |
| PE20080669A1 (es) | 2006-09-08 | 2008-07-18 | Drugtech Corp | Composicion de liberacion sostenida que comprende levodopa |
| CA2606658A1 (en) | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| WO2008124330A2 (en) | 2007-04-06 | 2008-10-16 | Transform Pharmaceuticals, Inc. | Systems and methods for delivering a fluid drug |
| CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| CN101669925B (zh) | 2008-09-10 | 2011-08-10 | 天津药物研究院 | 干粉吸入剂、其制备方法和用途 |
| WO2010055133A1 (en) | 2008-11-14 | 2010-05-20 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| ES2840748T3 (es) | 2009-05-19 | 2021-07-07 | Neuroderm Ltd | Composiciones para la administración continua de inhibidores de dopa decarboxilasa |
| CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| KR101187064B1 (ko) | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체 |
| US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| EP3326615B1 (en) | 2010-11-15 | 2020-01-08 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
| ES2673219T3 (es) | 2010-11-15 | 2018-06-20 | Neuroderm Ltd | Composición para la entrega transdérmica de agentes activos |
| CA2823642A1 (en) | 2010-12-10 | 2012-06-14 | Synagile Corporation | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| WO2013061161A2 (en) | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
| TR201204839A2 (tr) | 2012-04-25 | 2012-12-21 | Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. | Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu. |
| NZ703341A (en) | 2012-06-05 | 2016-11-25 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| WO2013184646A2 (en) | 2012-06-05 | 2013-12-12 | Synagile Corporation | Dosing regimens for subcutaneously infusible acidic compositions |
| CN110935026A (zh) | 2013-03-13 | 2020-03-31 | 纽罗德姆有限公司 | 帕金森病的治疗方法 |
| AU2015228369B2 (en) | 2014-03-13 | 2020-05-21 | Neuroderm Ltd | DOPA decarboxylase inhibitor compositions |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| KR20240113982A (ko) | 2014-10-21 | 2024-07-23 | 애브비 인코포레이티드 | 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도 |
| BR112018010564A2 (pt) | 2015-11-24 | 2018-11-21 | Neuroderm Ltd. | composições farmacêuticas compreendendo levodopa amida e usos das mesmas |
| WO2018154447A1 (en) | 2017-02-21 | 2018-08-30 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| WO2019038638A1 (en) | 2017-08-21 | 2019-02-28 | Neuroderm Ltd | PROCESS FOR PREPARING AMIDE OF PURIFIED LEVODOPA |
| AR112683A1 (es) | 2017-08-21 | 2019-11-27 | Neuroderm Ltd | Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende |
| AR112472A1 (es) | 2017-08-21 | 2019-10-30 | Neuroderm Ltd | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas |
-
2021
- 2021-05-28 US US17/334,554 patent/US11213502B1/en active Active
- 2021-11-16 MX MX2023005725A patent/MX2023005725A/es unknown
- 2021-11-16 CN CN202180090972.2A patent/CN117120045A/zh active Pending
- 2021-11-16 TW TW110142643A patent/TW202233171A/zh unknown
- 2021-11-16 EP EP21894184.7A patent/EP4247357A4/en active Pending
- 2021-11-16 JP JP2023529002A patent/JP2023552700A/ja active Pending
- 2021-11-16 CA CA3198748A patent/CA3198748A1/en active Pending
- 2021-11-16 KR KR1020237019830A patent/KR20230110542A/ko active Pending
- 2021-11-16 WO PCT/IL2021/051355 patent/WO2022107125A1/en not_active Ceased
- 2021-11-16 IL IL302826A patent/IL302826A/en unknown
- 2021-11-16 AU AU2021383322A patent/AU2021383322A1/en active Pending
- 2021-11-17 AR ARP210103172A patent/AR124078A1/es unknown
- 2021-11-23 US US17/533,984 patent/US20220151965A1/en not_active Abandoned
-
2024
- 2024-06-20 US US18/748,756 patent/US20250152534A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220151965A1 (en) | 2022-05-19 |
| JP2023552700A (ja) | 2023-12-19 |
| AU2021383322A1 (en) | 2023-06-22 |
| US11213502B1 (en) | 2022-01-04 |
| TW202233171A (zh) | 2022-09-01 |
| EP4247357A4 (en) | 2024-09-25 |
| WO2022107125A1 (en) | 2022-05-27 |
| KR20230110542A (ko) | 2023-07-24 |
| CN117120045A (zh) | 2023-11-24 |
| EP4247357A1 (en) | 2023-09-27 |
| CA3198748A1 (en) | 2022-05-27 |
| IL302826A (en) | 2023-07-01 |
| MX2023005725A (es) | 2023-05-25 |
| AU2021383322A9 (en) | 2024-10-10 |
| US20250152534A1 (en) | 2025-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124078A1 (es) | Método para el tratamiento de la enfermedad de parkinson | |
| BR112015022390A8 (pt) | uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson | |
| CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
| CL2020002026A1 (es) | Inhibidor de fap. | |
| MX336187B (es) | Metodo para tratar el mal de parkinson. | |
| CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| CL2023000289A1 (es) | Combinaciones para el tratamiento de cáncer | |
| MX2020010417A (es) | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret. | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| CO2025005378A2 (es) | Compuestos n-(5-sustituido-[(1,3,4-tiadiazolil) o (1,3-tiazolil)](sustituido)carboxamida, composiciones farmacéuticas y métodos de preparación de los compuestos amida y de su uso | |
| MX2019001412A (es) | Compuestos de 9-aminometil minociclina y usos de los mismos. | |
| CL2021001397A1 (es) | Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva | |
| BR112021017198A2 (pt) | Uso de vibegron para tratar bexiga hiperativa | |
| MX2023011720A (es) | Una composicion para su uso en el tratamiento de mhc-i-opatias. | |
| MX2024008375A (es) | Metodos y composiciones para el tratamiento de la enfermedad de parkinson. | |
| MX2021015390A (es) | Tratamiento para sinucleinopatias. | |
| MX2021013070A (es) | Farmaco terapeutico para discinesia. | |
| UY38473A (es) | Formulaciones farmacéuticas para una administración subcutánea | |
| NZ768098A (en) | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders | |
| CO2023009085A2 (es) | Pauta posológica de levodopa | |
| MX2025014594A (es) | Lanifibranor para uso en eltratamiento de vasodilatacion esplacnica en un paciente con una afeccion hepatica | |
| AR132431A1 (es) | Métodos y composiciones para reducir los síntomas de la enfermedad de parkinson | |
| AR117097A1 (es) | Formulaciones farmacéuticas para una administración subcutánea |